<DOC>
	<DOCNO>NCT01022853</DOCNO>
	<brief_summary>The primary objective current study investigate Maximum Tolerated Dose ( MTD ) term safety tolerability BI 6727 combination fix dose BIBF 1120 , patient advance metastatic solid tumour .</brief_summary>
	<brief_title>Combination BI6727 ( Volasertib ) BIBF1120 Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients confirm diagnosis advance , non resectable and/or metastatic solid tumour , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment 2 . Age &gt; = 18 year 3 . European Cooperative Oncology Group performance status &lt; = 2 4 . Written inform consent accordance International Conference Harmonization Good Clinical Practice ( ICHGCP ) local legislation 5 . Recovery Common Terminology Criteria Adverse Events grade 24 therapyrelated toxicity previous systemic anticancer therapy radiotherapy ( except alopecia ) Exclusion criterion : 1 . Serious illness concomitant nononcological disease consider investigator incompatible trial 2 . Known hypersensitivity trial drug excipients 3 . Treatment investigational drug participation interventional trial within 28 day first administration trial drug ( BIBF 1120 ) concomitantly trial 4 . Systemic anticancer therapy radiotherapy within 28 day start therapy concomitantly trial . The restriction apply steroid bisphosphonates 5 . Active infectious disease infection HIV I/II 6 . Other malignancy currently require another anticancer therapy 7 . Clinical evidence symptomatic progressive brain leptomeningeal disease past 6 month 8 . Known inherited predisposition bleed thrombosis 9 . Radiographic evidence cavitary necrotic tumour 10 . History clinically significant haemoptysis within past 3 month 11 . Centrally locate tumour radiographic evidence ( Computed Tomography Magnetic Resonance Imaging ) local invasion major blood vessel 12 . Absolute Neutrophil Count ( ANC ) less 1.5 x 1000000000/L 13 . Platelets Count ( PLT ) less 100 x 1000000000/L 14 . Total bilirubin &gt; upper limit normal ( ULN ) 15 . Alaninaminotransferase ( ALT ) and/or Aspartateaminotransferase ( AST ) &gt; = 1.5 x ULN ( case liver metastasis : ALT AST &gt; = 2.5 x ULN ) 16 . Serum creatinine &gt; 1.5 mg/dl 17 . Major injury and/or surgery bone fracture within 28 day first administration trial drug ( BIBF 1120 ) , plan surgical procedure trial period 18 . Known history clinically relevant QT prolongation ( e.g . long QT syndrome ) 19 . History severe haemorrhagic thromboembolic event past 6 month ( exclude central venous catheter thrombosis peripheral deep vein thrombosis ) 20 . Therapeutic anticoagulation ( except low dose heparin and/or heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose therapy acetylsalicylic acid &lt; = 325mg per day ) 21 . Active alcohol drug abuse 22 . Women men sexually active unwilling use medically acceptable method contraception trial 23 . Pregnancy breastfeed 24 . Patients unable comply protocol 25 . Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>